Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Eukaryotic surface display libraries: MerckRecent Research Landscape

Inefficient antibody screening cycles delay drug discovery and increase development costs. This lever utilizes yeast-based expression systems to enable rapid selection and secretion of full-length human IgG scaffolds.

What technical problems is Merck addressing in Eukaryotic surface display libraries?

Therapeutic antibody physical instability

(11)evidences

Antibody molecules are prone to aggregation, denaturation, and chemical degradation during storage. Maintaining structural integrity in high-concentration or multi-antibody formulations is necessary to ensure safety and therapeutic efficacy.

Therapeutic protein physical instability

(5)evidences

Liquid formulations of therapeutic antibodies suffer from physical and chemical degradation over time. Crystalline forms overcome these limitations to ensure long-term shelf life and high-concentration delivery.

Inadequate antibody folding and glycosylation

(4)evidences

Inconsistent post-translational modifications and glycan variability compromise therapeutic efficacy and product uniformity. Standardizing these attributes ensures predictable pharmacological performance and structural stability.